NCT06263114

Correlation of Blood Gene Expression (TruGraf Liver) With Liver Biopsy in Pediatric Liver Transplant Recipients

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 16 (actual)
• Sponsor: Children's Mercy Hospital Kansas City · Academic / Other
• Sex: All
• Age: 1 Year – 17 Years
• Healthy volunteers: Not accepted

Summary

Liver transplant rejection is when the body's immune system attacks and damages the liver of a transplant recipient. Currently the best way to see if that is happening is with a liver biopsy. The purpose of this research study is to see if a simple blood test can diagnose if a transplanted liver is being rejected.

Detailed description

This study is an investigator-initiated, prospective, single-cohort trial to assess the ability of the TruGraf® Liver gene expression panel (GEP) to predict rejection in pediatric liver transplant recipients undergoing surveillance and for-cause liver biopsy.

Conditions

• Liver Transplant; Complications
• Liver Failure, Acute

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	TruGraf® Liver gene expression panel (GEP)	Test done on blood sample collected during for cause or routine liver biopsy

Timeline

• Start date: 2024-01-01
• Primary completion: 2025-02-07
• Completion: 2025-02-07
• First posted: 2024-02-16
• Last updated: 2025-02-18

Locations

1 site across 1 country: United States